Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05128942 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children Aged 2-17 Years With CAH
A Phase 2 study, sponsored by Spruce Biosciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 67
- Enrollment target
NCT05128942 is a Phase 2 study that was terminated before completion, run by Spruce Biosciences. The registered enrollment target is 67 participants.
The verdict
NCT05128942, a Phase 2 study, was terminated before completion, sponsored by Spruce Biosciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 67 participants
- Enrollment target
Study Summary
An investigation of the safety and efficacy of tildacerfont in participants with CAH.
Interventions
- DRUG Tildacerfont
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2021-12-10 |
| Est. Completion | 2025-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05128942
The ClinicalTrials.gov registry entry for NCT05128942 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Spruce Biosciences, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tildacerfont is the first listed.
NCT05128942 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05128942 about?
NCT05128942 is a clinical study titled "A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children Aged 2-17 Years With CAH". An investigation of the safety and efficacy of tildacerfont in participants with CAH.
What is the current status of trial NCT05128942?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 67 participants. The study started on 2021-12-10. Estimated completion is 2025-01-31.
What interventions are being tested in trial NCT05128942?
The interventions under investigation include: Tildacerfont (DRUG).
Who is sponsoring clinical trial NCT05128942?
This trial is sponsored by Spruce Biosciences, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.